source
- FDA schedules advisory committee meetings for rejected Replimune melanoma drug and Capricor DMD cell therapyThe FDA announced that it will hold two advisory committee meetings this week to revisit investigational therapies that were previously turned down. One meeting will consider Capricor Therapeutics'…
- Almac Clinical Services podcast details end-to-end clinical trial supply chainAlmac Clinical Services released a six-part podcast that walks listeners through the clinical trial supply chain from protocol planning to patient delivery. The series, published by BioPharma Dive’…